Effective in skin types IV–VI where hydroquinone carries elevated risks.
First-choice brightener for Fitzpatrick IV–VI. Tolerable with retinoids and vitamin C in evening protocols. Pregnancy-safe (Category B).
If you're targeting melasma, this research supports adding azelaic acid to your AM/PM routine. Effective concentration range: 4% based on this study. Timeline to expect: 24 weeks based on study duration.
Translated from this study's findings, not a personal prescription. Pair with your existing protocol and your practitioner's guidance.
AzA 20% cream and 15% gel produce melasma improvement comparable to HQ 4% at 24 weeks across multiple trials. Mechanisms: competitive tyrosinase inhibition, mitochondrial enzyme interference, anti-keratinizing effect. Especially valuable in Fitzpatrick IV–VI where HQ-induced ochronosis is a concern.
Azelaic acid (AzA) is a dicarboxylic acid with tyrosinase-inhibiting, antioxidant, and anti-inflammatory activity. Multiple controlled trials demonstrate efficacy comparable to hydroquinone 4% in melasma at 24 weeks, with superior safety profile and no ochronosis risk. Effective in skin types IV–VI where hydroquinone carries elevated risks.
Original source →Skin dullness, characterized by pigmentation disorders and yellowing, is a major cosmetic concern in Asian populations. Lipofuscin exhibits ultraviolet (UV)/visible light spectral absorption, reduces skin reflectance, and contributes to dullness, whereas existing therapies targeting melanogenesis and glycation lack comprehensive efficacy. This study aimed to evaluate the multimodal anti-dullness effects of a novel formulation (HNHT: hyaluronic acid, niacinamide, hydrolyzed red algae, and tranexamic acid).
The combination of recombinant human epidermal growth factor (rhEGF) and fractional carbon dioxide (CO2) laser therapy is increasingly used in the treatment of facial atrophic acne scars. This study aimed to systematically assess the efficacy and safety of rhEGF combined with fractional CO2 laser therapy for managing facial atrophic acne scars. PubMed, Embase, the Cochrane Library, Web of Science, CNKI (China National Knowledge Infrastructure), Wanfang, SinoMed, and VIP were searched from inception to July 29, 2025.
L-Carnitine, an amino acid derivative critical for fatty acid metabolism, exhibits anti-inflammatory, antioxidant, and cytoprotective properties, with emerging applications in dermatology. This review explores its therapeutic potential, both topically and systemically, and its role as a biomarker in various skin disorders. A systematic search of Medline, EMBASE, and PubMed (1946-January 2025) was conducted, focusing on L-carnitine and dermatologic conditions, excluding acetyltransferases, acyltransferases, breast, and genetic metabolic diseases.
This information is for educational purposes only and is not medical advice. Individual results vary. Consult a qualified dermatologist or healthcare professional for medical concerns. Full disclaimer →